NL0011606264 - Common Stock
MERUS NV
NASDAQ:MRUS (5/15/2024, 7:00:01 PM)
After market: 45.21 0 (0%)45.21
+0.44 (+0.98%)
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 164 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.
MERUS NV
Uppsalalaan 17, 3rd & 4th floor
Utrecht UTRECHT 3584
P: 31850162500
CEO: Sven A. Lundberg
Employees: 164
Website: https://merus.nl/
• Le pétosemtamab obtient le statut de thérapie innovante pour le traitement d’un carcinome épidermoïde de la tête et du cou (CETC) précédemment traité ...
• Petosemtamab erhielt die BTD für die Behandlung von bereits behandeltem HNSCC UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 14, 2024 ...
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) --...
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées...
Petosemtamab in Kombination mit Pembrolizumab bei 1L (Erstlinientherapie) HNSCC – erste vorläufige klinische Daten auf der ASCO-Jahrestagung 2024;...
Here you can normally see the latest stock twits on MRUS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: